Ampio Pharmaceuticals Inc. – NYSE MKT: AMPE
The reason I have AMPE on my list is that there is a positive momentum in the news. More importantly, they have just put out the latest release on this in the past 15 days or so. Look at the last two press releases from AMPE.
Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial – (Wed, Aug 14)
Luoxis Diagnostics, Inc. announces positive results from first clinical study conducted with company’s proprietary diagnostic platform – (Thu, Jun 20)
I say the news is “positive” because even AMPE uses the word positive in its headlines. Also the product Ampion is achieving the results. A 40% reduction in pain with improvement in overall quality of life with few, if any, adverse reactions. What more could they ask for out of this trial?
The downside is that further trials will result in changed result. Another risk is readily apparent when you look at the chart:
You can see it has steadily moved up with the exception of a slight drop-off right before this latest update on August 14th. (That’s why we do not hold through likely updates.) The risk is that there is a lot of downside if the news suddenly changes.